Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|11|3|239-253

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.11, Iss.3, 2011-03, pp. : 239-253

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System

By  

Current Cancer Drug Targets, Vol. 14, Iss. 6, 2014-07 ,pp. : 517-536

Bentham Science Publishers

Access to resources Recommend Favorite

Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer

By  

Current Cancer Drug Targets, Vol. 13, Iss. 2, 2013-02 ,pp. : 175-187

Bentham Science Publishers

Access to resources Recommend Favorite

Sibutramine: current status as an anti-obesity drug and its future perspectives

By Sharma Bikash   Henderson David C  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 12, 2008-08 ,pp. : 2161-2173

Informa Healthcare

Access to resources Recommend Favorite

Novel Drug Delivery Systems for Sustained and Targeted Delivery of Anti-Cancer Drugs: Current Status and Future Prospects

By  

Current Drug Delivery, Vol. 7, Iss. 2, 2010-04 ,pp. : 152-161

Bentham Science Publishers

Access to resources Recommend Favorite

Anticancer Antifolates: Current Status and Future Directions

By  

Current Pharmaceutical Design, Vol. 9, Iss. 31, 2003-12 ,pp. : 2593-2613

Bentham Science Publishers

Access to resources Recommend Favorite